Ascentage Pharma Announces Publication of Preclinical Data in Nature Immunology Showing Enhanced T-Cell-Mediated Antitumor Immunity Induced by Its MDM2-p53 Inhibitor APG-115

SUZHOU, China and ROCKVILLE, Md., March 25, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced the peer-reviewed...

from PR Newswire: https://ift.tt/3fj7o7U